Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of several malignancies, the role of immunotherapy in biliary tract cancer (BTC) is currently under investigation and ICIs are still looking for their niche in this setting. In this Editorial, we discuss recently published data regarding ICIs in BTC, with a particular focus in terms of selection of patients and biomarker-driven trials.
Ricci A.D., Rizzo A., Brandi G. (2020). Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look. CANCER CONTROL, 27, 1-3 [10.1177/1073274820948047].
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
Ricci A. D.;Brandi G.
2020
Abstract
Although immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape of several malignancies, the role of immunotherapy in biliary tract cancer (BTC) is currently under investigation and ICIs are still looking for their niche in this setting. In this Editorial, we discuss recently published data regarding ICIs in BTC, with a particular focus in terms of selection of patients and biomarker-driven trials.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Immunotherapy in Biliary Tract Cancer.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale (CCBYNC)
Dimensione
137.9 kB
Formato
Adobe PDF
|
137.9 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
